Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVDX3 in distal radius fractures
NCT05987033Phase 2Completed
- Sponsor
- Novadip Biosciences
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Implantable Devices, Implantable Hydrogels, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NVD-X3 in distal radius fracture, sponsored by Novadip Biosciences. Primary endpoint: Serious Treatment-emergent Adverse Events and NVDX3-related Treatment-emergent Adverse Events at 12 months. Started Aug 2023; status: completed.
02
Drugs
NVD-X3
03
Conditions
distal radius fracture
Beyond the preview
Go deeper on NCT05987033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987033.